There is interest in developing inhibitors of human group III secreted phospholipase A 2 (hGIII-sPLA2) because this enzyme plays a role in mast cell maturation. There are no potent inhibitors for hGIII-sPLA2 reported to date, so we adapted a fluorescence-based enzyme activity monitoring method to a high-throughput screening format. We opted to use an assay based on phospholipid substrate present in phospholipid vesicles since this matrix more closely resembles the natural substrate of hGIII-sPLA2, as opposed to phospholipid/detergent mixed micelles. The substrate is a phospholipid analogue containing BODIPY fluorophores dispersed as a minor component in vesicles of nonfluorescent phospholipids. Action of hGIII-sPLA2 liberates a free fatty acid from the phospholipid, leading to a reduction in quenching of the fluorophore and hence an increase in fluorescence. The assay uses optical detection in a 1536-well plate format with an excitation wavelength far away from the UV range so as to minimize false-positive library hits that result from quenching of the fluorescence. The high-throughput screen was successfully carried out on a library of 370,276 small molecules. Several hits were discovered, and data have been uploaded to PubChem. This study describes the first high-throughput optical screening assay for secreted phospholipase A 2 inhibitors based on a phospholipid vesicle substrate.
Introduction
Secreted phospholipases A 2 (sPLA2s) are a class of Ca 2+dependent enzymes that release fatty acids from the sn-2 position of glycero-phospholipids. 1 Humans contain several sPLA2s that fall into three structural groups (groups I, II, V, and X; group III; group XII), but all share a similar active site in which Ca 2+ functions to help bind a phospholipid substrate to the active site and also plays a catalytic role. 2 Several inhibitor classes for sPLA2s have been reported, 3 but none have been found to inhibit group III sPLA2. We are interested in developing inhibitors of human group III sPLA2 (hGIII-sPLA2) because this enzyme is involved in mast cell function and maturation, and hence inhibitors may be useful anti-mast cell therapeutics. 4 Inhibitors of sPLA2s are more difficult to analyze than inhibitors of many enzymes because they act at the lipidwater interface (interfacial enzymes). Many inhibitors act as nonspecific agents that cause desorption of the enzyme from the interface. 5 Most previously reported assays for sPLA2s are not well suited for high-throughput assays of compound libraries. Many lack sensitivity and thus require impractical amounts of enzyme to screen hundreds of thousands of compounds. High-throughput screening (HTS) assays are commonly carried out with fluorescence-based optical readouts. Among fluorescence-based sPLA2 assays, the one based on pyrene-containing phospholipids is sufficiently sensitive and adaptable to small-volume assays in microtiter plates 6 but is not appropriate for HTS because excitation occurs in the near-UV, and thus there will be optical quenching with a large number of test compounds in the library. Furthermore, this assay uses a high amount of serum albumin in the aqueous phase to trap the fluorescent product, and this protein is well known to bind to many drug-like molecules.
In this article, we report the adaptation of an assay (MP07701; Molecular Probes (Eugene, OR) for sPLA2s that has all of the properties desired for a high-throughput assay: (1) the assay is sufficiently sensitive so that a reasonable amount of enzyme is needed, (2) the assay is easy to execute and miniaturize, (3) the fluorescence excitation and emission are well into the visible range where quenching is less of a problem, and (4) the assay uses phospholipid vesicle substrate, thus allowing compounds to be tested in a matrix that well resembles the natural environment of sPLA2s.
Materials and Methods

Materials
Commercial lipids were as follows: Red/Green BODIPY PC-A2 (part A10072; Molecular Probes, Eugene, OR); BODIPY Fluorescence Product (BODIPY FL C5) (part D3834; Molecular Probes, Eugene, OR); dioleoylphosphatidylcholine (DOPC) (part 850375; Avanti Polar Lipids, Alabaster, AL); dioleoylphosphatidylglycerol (DOPG) (part 840475; Avanti Polar Lipids, Alabaster, AL). Other reagents and supplies were: Tris (part 0497; Amresco, Solon, OH); NaCl (part 7581, Macron Fine Chemicals, Avantor, Center Valley, PA); CaCl 2 (calcium chloride pellets) (part 1313; J.T. Baker, Avantor, Center Valley, PA); ethylene-bis(oxyethylenenitrilo)tetraacetic acid (EGTA) (part 03779; Sigma-Aldrich, St. Louis, MO); 96-well plates black (part 6005279; PerkinElmer, Waltham, MA).
Recombinant hGIII-sPLA2
Expression of hGIII-sPLA2 in Escherichia coli has been previously described. 7 Inclusion bodies were isolated as described. 8 The inclusion body pellet was dissolved in 35 mL of 6 M guanidine-HCl, 0.3 M sodium sulfite, and 50 mM Tris (pH 8.0) using a Dounce homogenizer and sonication. The mixture was treated with Thanhauser reagent. Full details have been published. 8 The mixture was centrifuged for 20 min at 10,000 rpm at 4 °C to remove insolubles, and the supernatant was subjected to refolding using the dialysis method 8 with refolding buffer consisting of 0.9 M guanidine-HCl, 50 mM Tris (pH 7.0), 0.8 M L-arginine, 6 mM L-cysteine, 5 mM L-methionine, 1 mM EDTA, and 0.1 M sulfobetaine SB 12 (Sigma-Aldrich, St. Louis, MO). After 3 h of refolding at room temperature, the mixture was removed from the bag and concentrated by ultracentrifugation using a YM-10 membrane (EMD Millipore, Billerica, MA). The concentrate was dialyzed against 20% acetonitrile/0.1% trifluoroacetic acid/5 mM L-methionine. The dialyzed solution was filtered to remove particulate (0.2-micron nylon-66 membrane) and submitted to high-performance liquid chromatography (HPLC) purification on a C18 Symmetry Shield column (Waters Corp., Milford, MA) using a gradient of 20% to 30% acetonitrile in water with 0.1% trifluoroacetic acid. Purity of hGIII-sPLA2 was estimated at 95% by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). sPLA2s are very stable proteins, and we have shown in several previous publications that they can be purified in native form using the methods described above. They have at least five disulfides. Mass spectrometry analysis of our purified sPLA2s, including group III sPLA2, shows that all disulfides are formed. This has been published previously. 8 
96-Well Plate hGIII-sPLA2 Inhibition Assay
Protein concentrations were measured with the Bradford dye reagent (Bio-Rad, Hercules, CA) using bovine serum albumin as a standard. hGIII-sPLA2 solution (1 mg/mL) was stored at −80 °C and was thawed on ice prior to assay. hGIII-sPLA2 assay buffer was prepared as 50 mM Tris HCl (pH 8.9), 100 mM NaCl, and 1 mM CaCl 2 . hGIII-sPLA2 stop buffer was prepared as 20 mM EGTA in 50 mM Tris-HCl and 100 mM NaCl. Fresh before use, the hGIII-sPLA2 solution was diluted with hGIII-sPLA2 assay buffer to a concentration of 14 µg/mL (7 µg/mL final concentration). Test compounds were dissolved and diluted in DMSO (typical stock solution 1 mM in DMSO). Then, 1 µL of compound solution and 49 µL of enzyme solution were combined in the well of a black 96-well plate and incubated at room temperature (25 °C) for 15 min. To generate the control wells, hGIII-sPLA2 stop buffer (20 µL) was added to a well containing 49 µL enzyme solution and 1 µL DMSO. During the incubation period, the BODIPY substrate solution in a suspension of liposomes was made as follows. Red/Green BODIPY PC-A2 (1 mM in DMSO), DOPC (10 mM in ethanol), and DOPG (10 mM in ethanol) were thawed to room temperature (25 °C). Solutions containing BODIPY reagents were protected from light. Red/ Green BODIPY PC-A2 (6.5 µL), DOPC (6.5 µL), and DOPG (6.5 µL) were combined in a 1.5-mL conical polypropylene microfuge tube. The tube was flicked by hand several times to mix the substrate solution. After a brief centrifugation to bring the fluid to the bottom of the tube, 18 µL was removed and mixed with 982 µL of assay buffer, and the mixture was vortexed briefly (this gives 6 µM Red/ Green BODIPY PC-A2 and 60 µM DOPC and DOPG). This substrate solution (50 µL) was added to the well containing hGIII-sPLA2 and inhibitor after the 15-min incubation period (see above) to start the reaction. The assay was incubated at room temperature (25 °C), protected from light, for 35 min. Stop buffer (20 µL per well) was then added to all wells (except for control wells, in which it was already present). The assay was incubated for an additional 10 min, and the plate was read on a UV/VIS fluorimeter (Victor 3 V; PerkinElmer) with 485 nm excitation and 535 nm emission.
96-Well Plate hGIII-sPLA2 Counterscreen Assay
Compounds that display a false-positive inhibition due to quenching of the fluorescent product released by the enzyme were identified using the following counterscreen method. The assay was run as previously described along with an additional well per test compound that contained 1 µL test compound in DMSO, 49 µL enzyme solution, 50 µL BOPIDY:DOPC:DOPG substrate solution (as above) but containing 300 nM BODIPY Fluorescence Product, and 20 µL stop buffer. The BODIPY Fluorescence Product was added from a 1-mM stock solution in DMSO. The amount of BODIPY FL C5 per well (150 nM) was determined by varying the concentration of BODIPY FL C5 until the fluorescence response matched that of the uninhibited enzyme.
1536-Well hGIII-sPLA2 Inhibition HTS Assay
The 96-well assay was miniaturized to the 1536-well plate format requiring some modifications, which resulted in the final conditions listed in Supplemental Table S1 . hGIII-sPLA2 enzyme was prepared in assay buffer (50 mM Tris-HCl [pH 8.9], 100 mM NaCl, and 1 mM CaCl 2 ) to a concentration of 2.63 µg/mL. Prior to the start of the assay, 2 µL assay buffer was dispensed into control wells located in columns 1 through 3 of 1536-well black solid-bottom microtiter plates. Next, 2 µL assay buffer containing 2.63 µg/mL hGIII-sPLA2 enzyme was dispensed into the remaining columns. Then, 37 nL test compound in DMSO or DMSO alone (1.2% final concentration) was added to the appropriate wells using the automated GNF/Kalypsys (San Diego, CA) robotic platform. Plates were incubated for 15 min at 25 °C. The BODIPY substrate solution in a suspension of liposomes was prepared following the same procedure as in the 96-well method. Then, the appropriate volume from the substrate solution was added and mixed in assay buffer. The lipid substrate mixture was vortexed briefly. This mixture yielded a 5:5:1 DOPC:DOPG:BODIPY PC-A2 ratio. The assay started by the addition of 1 µL of 9 µM BODIPY PC-A2 substrate incorporated in liposomes containing 45 µM DOPC and 45 µM DOPG in assay buffer to all wells. Plates were centrifuged, and after 35 min of incubation at 25 °C, fluorescence was measured at 485 nm excitation and 535 nm emission using a ViewLux plate reader (PerkinElmer). Further details of this assay procedure can be found at the PubChem AID 743126 (https://pubchem.ncbi.nlm.nih.gov/assay/assay. cgi?aid=743126) and are also listed in Supplemental Table  S1 .
Screening Data
Raw fluorescent data were uploaded into the Scripps Research Institutes Molecular Screening Center (SRIMSC) HTS database (Symyx, Santa Clara, CA). Activity of each well was normalized on a per plate basis using the following equation:
where Test well is defined as wells containing hGIII-sPLA2 enzyme in the presence of test compound and BODIPY PC-A2 substrate. Low Control is defined as the median of the wells containing test compounds, and High Control is defined as the wells containing DMSO and BODIPY PC-A2 but no hGIII-sPLA2. Data were normalized on a per plate basis, and each assay plate underwent a quality control check. A value greater than 0.5 for Z′ was required before further testing. 9 For the primary screen, test compounds from the library were screened in singlicate at a final nominal concentration of 12.2 µM (final DMSO concentration of 1.2%). Well fluorescence was measured with a ViewLux plate reader (PerkinElmer), and the percent inhibition of each test compound was calculated on a per plate basis. A mathematical algorithm was used to determine nominally inhibiting compounds in the primary screen. Four values were calculated to determine an interval based cutoff: (1) the average percent inhibition of all high controls tested plus three times the standard deviation of the high controls, (2) the average percent inhibition of all low controls tested minus three times the standard deviation of the low controls, (3) the average percent inhibition of all compounds tested between (1) and (2), and (4) three times their standard deviation. The sum of two of these values, (3) and (4), was used as a cutoff parameter. Any compound that exhibited greater percent inhibition than the cutoff parameter was declared active.
For dose-response experiments, the average of triplicate well data was plotted against compound concentration. A four-parameter equation describing a sigmoidal doseresponse curve was fitted using Assay Explorer software (MDL Information Systems; Symyx). All further results from the screens can be found at the National Institute of Health's (NIH's) PubChem website (http://pubchem.ncbi. nlm.nih.gov/) using the AID listed in the Supplemental  Table S2 .
A two-way Venn diagram generator was used to crosscompare data from the hGIII-sPLA2 confirmation and substrate counterscreen assays. Each of the assays was run at the SRIMSC and previously published in PubChem (AIDs 743126,743280, 743282, 743457, and 743455). The tool used is freely available and can be found at http://www. pangloss.com/seidel/Protocols/venn4.cgi.
Screening Library
The Molecular Libraries Small Molecule Repository (MLSMR) library was provided by BioFocus DPI (South San Francisco, CA) through the NIH's Roadmap Molecular Libraries Initiative. Details regarding compound selection for this library can be found online at http://mli.nih.gov/mli/ compound-repository/mlsmr-compounds/. At the time of this assay, the library consisted of 370,276 small molecules (more than 50% in the molecular weight range 350-410 g/ mol) and comprises both synthetic and natural products, from either commercial or academic sources, that can be grouped into the following categories: specialty sets of known bioactive compounds such as drugs and toxins (0.65%), focused libraries aimed at specific target classes (2.85%), noncommercial sources (7.4%), and diversity sets covering a large area of the chemical space (89.1%).
HTS Confirmation and Tertiary Assays
The confirmation screen was run under the same conditions as the primary HTS, except that plates were assessed in triplicate, and results for each compound were reported as the average percent inhibition of the three measurements, plus or minus the associated standard deviation (PubChem AID 743280). For titration experiments, assay protocols were identical to those described above, with the following exception that compounds were prepared in 10-point, 1:3 serial dilutions starting at a nominal test concentration of 120 µM and assessed in triplicate using known methods 10 (PubChem AIDs 743457 and 743455).
Results and Discussion
Assay Principle
The structure of Red/Green BODIPY PC-A2 is shown in Figure 1 along with the product (BODIPY FL C5) released by the action of hGIII-sPLA2. Intramolecular fluorescence energy transfer between the two fluorophores of Red/Green BODIPY PC-A2 leads to low fluorescence. Formation of the free fatty acid product leads to an increase in fluorescence due to spatial separation of the two fluorophores. Susceptibility to compound interference is always a concern, and generally the higher the spectral emission of a fluorophore, the less likely a compound will interfere. A key advantage of BODIPY FL C5 is that excitation and emission maxima are well into the visible range, and thus there should be minimal interference from compounds in the test library that absorb in the UV-visible region. However, the possibility of interference is still relevant but is also concentration dependent. Here we set the substrate concentration at 3 µM, and generally as the concentration of the fluorophore increases, the contribution from fluorescent compounds should be reduced. If readily available, we may have chosen a probe that emits at a longer wavelength, known to help reduce compound interference because the intensity of scatter light decreases with increasing wavelength based on the Rayleigh principle. 11 Some of the compounds contained in the screening library may emit light in the region of our fluorescence assay response and thus lead to a false-negative result. To take measures to prevent this, fluorescence would need to be measured at time zero (before addition of the enzyme) and at the end point of the assay. The presence of a fluorescent compound would presumably shift the fluorescence upward at both time points and to the same extent. In the high-throughput screen, the fluorescence at time zero was not measured, and we decided to live with the possibility of false negatives rather than collecting twice as much fluorescent data. The results of the high-throughput screen show that fluorescent compounds (compounds with negative inhibition beyond the low control + 3 SD) tended to be more prevalent than putative quenchers. This was observed during the HTS campaign since 18,801 compounds had activity below three standard deviations plus the average of the sample field (<−19.21%). Thus, by employing a signal increase assay as opposed to a signal decrease assay, we were able to avoid false positives due to the presence of fluorescent compounds.
To rule out quenchers (compounds that did not inhibit the enzymatic activity but instead quenched the fluorescence of the BODIPY FL C5 product), we developed a counterscreen in which no enzyme was present. The amount of BODIPY FL C5 found to produce the same signal as that released by the uninhibited enzyme was incubated with the hits verified in the triplicate primary confirmation screen. A change in fluorescence of the enzymatic product by the library compound tells us if the compound itself reduces light emitted in the fluorescence channel of the instrument.
In this study, we adapted an assay for sPLA2s to an HTS platform based on phospholipids present in the form of lamellar vesicles. Some reported assays of sPLA2s rely on mixed-micelle substrate in which a small relative amount of phospholipid is dispersed in an excess of detergent as micelles. While the latter may be relevant to the action of pancreatic sPLA2 on phospholipid-bile salt mixed micelles, the group III sPLA2 acts on a cellular context and will presumably always act on phospholipids in cell membranes. In this article, we document that a high-throughput assay using lamellar phospholipid vesicles is feasible.
We chose to use Red/Green BODIPY PC-A2 as a minor component in vesicles of DOPC/DOPG so that phospholipid vesicles with a well-defined lamellar structure would be formed (in case the fluorescent phospholipid did not form well-structured vesicles). A second feature is that all known mammalian sPLA2s bind tightly to the interface of vesicles that contain a critical amount of the anionic phospholipid DOPG. 7, 8 Tight binding to the vesicle interface is important for sPLA2 inhibitor analysis, since many compounds inhibit these enzymes by the nonspecific effect of causing desorption of enzyme from the interface into the aqueous phase, and we are more interested in true competitive inhibitors that bind in the active site slot of sPLA2 bound at the lipid-water interface. 5 Recently, there has been a report of an assay platform that incorporated sPLA2 as a reporter enzyme. 12 This assay screened for inhibitors of deubiquitylase (DUB) using a substrate composed of ubiquitin (Ub) or a ubiquitin-like protein (UBL) fused to the N-terminus of an sPLA2, rendering the sPLA2 inactive. Cleavage of the Ub-sPLA2 substrate by DUB released the sPLA2, which cleaved the fluorescent reporter NBD C6-HPC, generating a signal that was linear with DUB concentration. In this study, the fluorescent lipid appears to be simply dispersed from a solid into an aqueous buffer. This probably leads to the formation of multilamellar vesicles. In contrast, in our study, we used the ethanol dilution method, which is a reliable way to obtain unilamellar vesicles. In addition, we did not use pure fluorescent phospholipid but rather a minor amount of the fluorescent phospholipid dispersed in nonfluorescent phospholipids that are well known to form well-defined, unilamellar vesicles.
Performance of the 96-Well Plate Assay
Supplemental Figure S1 shows the reaction time course measured with the 96-well plate assay as a function of the amount of hGIII-sPLA2. Supplemental Figure S2 shows that the reaction progress ceases immediately following addition of EGTA, which chelates the catalytic cofactor Ca 2+ . An amount of hGIII-sPLA2 of 0.7 µg per well and a quench time at 35 min were chosen for all fixed time point assays. Supplemental Figure S3 shows that the fluorescence in the fixed time point assay varies linearly with the amount of added hGIII-sPLA2.
The robustness and reproducibility of the 96-well assay were examined by determining the Z′ value. 9 The fluorescence response at 35 min of 10 replicates containing 0.7 µg hGIII-sPLA2 per well, five preincubated with stop buffer and five in which stop buffer was added at 35 min, was used to determine a Z′ value of 0.90. Next, we tested the compound indoxam, a well-known inhibitor of many sPLA2s. 13 This compound dose-dependently inhibited hGIII-sPLA2 in the 35-min fixed time point assay with an IC 50 of 24 µM (not shown). When 24 µM indoxam was added to the counterscreen, the fluorescent signal was reduced by only 11%, showing that the inhibitor blocks the action of hGIII-sPLA2 rather than quenching the fluorescence emission from the BODIPY FL C5 product. We also showed that inclusion of DMSO in the assay buffer up to 1.5% had no effect on the assay response (Suppl. Fig. S4) . We also showed that the difference in Z′ value is minimal whether no enzyme is used as the control or enzyme plus stop buffer is used as the control (Suppl. Fig. S5 ).
hGIII-sPLA2 1536-Well Assay Optimization
Miniaturization of the assay to the 1536-well plate format (Suppl. Table S1) required the reoptimization of the hGIII-sPLA2 enzyme concentration. Using the original assay conditions, it was observed that the signal-to-blank was 2-fold higher than the 96-well signal-to-blank when testing at the same hGIII-sPLA2 enzyme concentration at 7 µg/mL. An enzyme titration test (Suppl. Fig. S6A ) was performed to determine the optimal enzyme concentration and incubation time. To conserve enzyme while preserving or potentially increasing assay sensitivity, we reduced the enzyme concentration in the 1536-well assay to 1.75 µg/mL. At 35 min of incubation, the reaction was linear with respect to all enzyme concentrations tested for sPLA2 ( Suppl. Fig. S6B) . hGIII-sPLA2 stop buffer (20 mM EGTA in 50 mM Tris-HCl, 100 mM NaCl) was tested side-by-side with no enzyme control in the 1536-well format, and no difference was observed in the assay (data not shown). To reduce the volume of the assay, no enzyme was used as the positive control (instead of the enzyme plus stop buffer) for the remainder of 1536well assays. In addition, as opposed to the 96-well format, stop buffer was not used to stop the enzymatic reactions because the plates were read immediately upon completion of the 35-min incubation period.
Performance of the 1536-Well HTS Assay
To reduce the cost and increase the throughput of the HTS campaign, the assay was miniaturized and implemented in 1536-well plate format. Optimization of the assay was performed as described above during assay implementation to achieve the appropriate sensitivity and separation between controls. Two sets of controls, n = 24 per set, were placed on every assay plate: the high control (no enzyme) and the low control (enzyme), with both controls containing DMSO (1.2% final). These controls were used to ensure hGIII-sPLA2 activity, normalize the data, and monitor the data quality by measuring Z′ and signal-to-blank. While using such controls can artificially inflate Z′ values, they do provide a reasonable gauge of assay robustness, particularly when more appropriate small-molecule or specific ligand controls are unavailable. All primary HTS data were normalized to the no-enzyme control vs. enzyme and were used to produce a scatterplot to aid in visualization of the activity across the HTS campaign (Fig. 2) . To help remove fluorescence artifacts, a counterscreen assay was implemented in a 1536-well plate format using the BODIPY fluorescence product in the absence of hGIII-sPLA2 enzyme at the HTS secondary and tertiary stages. This assay measures changes in fluorescence signal in the absence of the enzyme. To use this assay as a counterscreen, a titration of the BODIPY fluorescence product was performed to achieve a fluorescence signal equivalent to the completed reaction when the enzyme is present in the reaction. All subsequent experiments were performed using the conditions listed in Supplemental Table S1 .
The hGIII-sPLA2 primary assay and counterscreen assay were implemented at a final assay volume of 3 µL/well in 1536-well plates. The primary assay was screened against the entire available MLSMR collection; 370,276 unique compounds were tested. All MLSMR compounds were screened at 12.2 µM. The median of the wells containing test compounds was used as a low control. Using these controls, the hGIII-sPLA2 assay demonstrated robust screening statistics. It had an average signal-to-background ratio (S/B) of 1.91 ± 0.07 and a Z′ of 0.81 ± 0.04 (n = 306 plates).
Selection of Hits
The hGIII-sPLA2 inhibition screening campaign is summarized in Supplemental Table S2 . All compounds were .21%, which is the average + 3 SD of the data wells. Compounds with inhibition above this line were considered primary active hits. Using the cutoff of 19.21%, 2,090 compounds were identified as hits.
tested at a nominal concentration of 12 µM. From the primary screen, 2,090 compounds (i.e., 0.56% of the total library) were identified as actives, exhibiting a percent inhibition greater than the nominal hit cutoff of 19.21%. We chose this cutoff using the interval-based method 14 to take advantage of eliminating extreme outliers in activity, either positive or negative, thus preserving the less active compounds closer to the baseline for further study. Of these, 1972 were available from the MLSMR for testing at the confirmation and counterscreen stages (Fig. 3) . To confirm inhibitory activity and to eliminate fluorescence artifacts, the 1972 samples were retested in triplicate in two different assays: (1) the original primary assay and (2) the substrate fluorescence counterscreen assay. The hGIII-sPLA2 inhibitor confirmation assay performance was consistent with an average Z′ of 0.82 ± 0.03 and a signal-to-blank of 1.68 ± 0.02. The primary assay hit cutoff was applied to the confirmation assay, which was 19.21%. The counterscreen assay performance was robust with an average Z′ of 0.90 ± 0.01 and a signal-to-blank of 2.73 ± 0.15. The counterscreen, which had not been previously tested against numerous compounds, required a method to determine a cutoff that would rule out artifacts efficiently and specifically while not being overzealous. The cutoff for the counterscreen used to qualify active compounds was the average percent inhibition of all wells containing DMSO only plus three times their standard deviation (5.92%) (PubChem AID 743282). This identified 167 hits or 8.47% of the compounds that exhibited at least moderate fluorescence quenching. This also validates the effectiveness of using the BODIPY PC-A2 as a probe as it was minimally affected by fluorescent artifacts.
This yielded 551 compounds out of the 680 (Suppl .  Table S2 ) that confirmed activity against hGIII-sPLA2 and that were not active in the counterscreen. Compounds (129) found to be active in the counterscreen assay were eliminated from further follow-up. Confirmed and counterscreen inactive compounds identified at this stage were prioritized for concentration response curve (CRC) studies (275 compounds). This number was limited as part of the MLSMR effort. To facilitate compound selection for titration studies, the 551 compounds were classified into 84 clusters based on their most common substructure. 15 Based on this analysis, 61 clusters were represented in the final compound selection for dose response (73%). Under these criteria, 275 compounds were selected for IC 50 titration, of which 240 compounds were available for further testing. See Figures  3 and 4 for a summary.
The CRCs for the 240 compounds were determined via testing in triplicate 10 a 10-point, 3-fold serial dilution format against both primary and counterscreen assays. The dose-response and counterscreen assays yielded satisfactory performance with an average Z′ of 0.77 ± 0.03 and an S/B of 2.04 ± 0.03 for the primary assay and a Z′ of 0.87 ± 0.01 and an S/B of 2.94 ± 0.08 for the counterscreen assay. Individual CRCs offered better insight into individual compound inhibition profiles between the primary and counterscreen assays, facilitating the triage of fluorescence artifacts such as CID "5399788," a possible fluorescence quencher based on comparable inhibition in the primary and counterscreen assays (Suppl . Table S3 ). Further analysis, such as promiscuity and identification of pan-assay interference compounds (PAINS) 16 values, was established to help remove nonspecific compounds that appeared as screening hits in these biochemical HTS assays. From the 240 compounds tested at this stage, 45 compounds were considered PAINS, which equates to ~18% of the total compounds tested. Promiscuity data analysis was performed by analyzing how many times a compound was considered active over the total of screened MLPCN PubChem assays. For this effort, it was found that most of the compounds (209) had low promiscuity (i.e., were active in ≤10% of the assays tested). As routine for the Roadmap initiative dose-response results, compounds that yielded IC 50 values below 10 µM were considered "active." For this HTS campaign, only one compound had an IC 50 <10 µM and was inactive in the counterscreen assay. However, 72 compounds with an IC 50 >10 µM in the primary assay exhibited an average maximum response >50% in the primary assay and <50% in the counterscreen assay. From those, there were 16 compounds with IC 50 values between 10 and 30 µM with more than 3-fold selectivity between primary and counterscreen assays (Suppl .  Table S3 ). Some of these compounds are of interest and are being considered for further characterization in the low-throughput assays and structure-activity relationship (SAR) studies (Fig. 4) .
Evaluation of Hits
Hits obtained from the high-throughput screen (Fig. 4) were tested in an orthogonal assay to confirm sPLA2 inhibition. A well-established assay for PLA2 activity on [ 3 H]-oleic acidlabeled E. coli membranes 17 (see also supplemental materials) was employed for this purpose. This assay measures the release of radiolabeled oleic acid from autoclaved membranes derived from E. coli that have been grown in the presence of tritiated oleic acid. After incubation with sPLA2, membranes are centrifuged, and released [ 3 H]-oleic acid in the supernatant is measured by scintillation counting. It should be noted that compound E (Fig. 4) was not available for further testing. The data confirm that compounds representing clusters A, C, D, and F are inhibitors of hGIII-sPLA2 (Suppl . Table S4 ). The compound representing cluster B was not found to inhibit hGIII-sPLA2 in this assay.
Hits obtained from the high-throughput screen (Fig. 4 ) were further analyzed for specificity by testing their ability Representive compounds for the top six most populated clusters (A-F) are shown with their structures, averaged maximum percent response, and the IC 50 values. All these compounds have an activity >50% in the hGIII-sPLA2 primary assay and low activity (<50%) in the counterscreen assay. For cluster A, compound CID 404404 was identified as a hit with an IC 50 <10 µM. For cluster B, compound CID 2211008 displayed high activity based on the averaged maximum response (92%) but with a final IC 50 >10 µM (18.8 µM). Compounds named CID 12005954, 3138378, 45281797, and 2927522 had an averaged maximum response between 60% and 75% with an IC 50 in the range of 20 to 30 µM (C-F). Note: Raw IC 50 data were obtained by fitting nonnormalized data to provide a point of reference compared to IC 50 data. Compounds that do not reach high levels of inhibition compared to the controls can still be fairly active so long as they exhibit an upper and lower asymptote. All these compounds have some structure-activity relationship based on the number of compounds represented in each cluster number assigned by the clustering algorithm; all results are provided in the supplemental section.
to inhibit two other mammalian sPLA2s, human group IIA and human group X sPLA2s (Suppl . Table S5 ). The data show that compounds C and D are selective for group III sPLA2 over groups IIA and X sPLAs. This suggests that they are not promiscuous compounds that work by nonspecific mechanisms such as destruction of phospholipid vesicle structure. Compounds A and F are pan-specific, active on all three sPLA2s, and are therefore less interesting.
The logP value for each compound was calculated using Collaborative Drug Discovery (CDD) software (Suppl .  Table S6 ). All compounds satisfied Lipinski's rule for oral drug bioavailability. The compounds were also tested for solubility in water and assay buffer by visual inspection over a range (10-100 µM) of concentrations (Suppl . Table  S6 ). All compounds were observed to be soluble under assay conditions at their IC 50 concentrations.
In conclusion, this study describes the first high-throughput optical screening assay for secreted phospholipase A 2 inhibitors based on a phospholipid vesicle substrate. The screen displayed acceptable statistics and allowed us to carry out a successful analysis of a large library of compounds. A few hits emerged that will set the stage for a medicinal chemistry campaign in attempts to develop the first potent inhibitor of hGIII-sPLA2.
